CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Pyrazinamide

吡嗪酰胺 杂质对照品Pyrazinamide Impurities

EP16 个杂质条目16 impurity entries

本页汇总 吡嗪酰胺 的 16 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 16 impurity reference standards of Pyrazinamide with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 吡嗪酰胺(Pyrazinamide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsDevelopment and Validation of an HPLC Method for Simultaneous Determination of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride in Pharmaceutical Formulations
    Journal of AOAC International · 2015 · Chellini PR et al.  ·  PMID 26525241  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020 · Zheng X et al.  ·  PMID 33091676  ·  DOI
  3. 分析方法Analytical MethodsOptimization of a stability-indicating HPLC method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks
    Journal of chromatographic science · 2007 · Glass BD et al.  ·  PMID 17254382  ·  DOI
  4. 分析方法Analytical MethodsTheoretically Guided Analytical Method Development and Validation for the Estimation of Rifampicin in a Mixture of Isoniazid and Pyrazinamide by UV Spectrophotometer
    Frontiers in chemistry · 2017 · Khan MF et al.  ·  PMID 28503547  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of pyrazinamide Mannich bases and its antitubercular properties
    Bioorganic & medicinal chemistry letters · 2006 · Sriram D et al.  ·  PMID 16464574  ·  DOI

吡嗪酰胺 —— 原料药与杂质对照品Pyrazinamide — drug substance & impurities

共 17 个条目(含原料药本体)17 items incl. the drug substance
Pyrazinamide structure
EP原料药 APIAPI
吡嗪酰胺Pyrazinamide
Pyrazinamide
CAS No.98-96-4
Chemical FormulaC5H5N3O
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 1 (Pyrazinamide EP Impurity A) structure
EPA
吡嗪酰胺杂质1(吡嗪酰胺EP杂质A)Pyrazinamide Impurity 1 (Pyrazinamide EP Impurity A)
Pyrazinamide Impurity 1 (Pyrazinamide EP Impurity A)
CAS No.98-97-5
Chemical FormulaC5H4N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 2 (Pyrazinamide EP Impurity B) structure
EPB
吡嗪酰胺杂质2(吡嗪酰胺EP杂质B)Pyrazinamide Impurity 2 (Pyrazinamide EP Impurity B)
Pyrazinamide Impurity 2 (Pyrazinamide EP Impurity B)
CAS No.19847-12-2
Chemical FormulaC5H3N3
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 3 structure
3
吡嗪酰胺杂质3Pyrazinamide Impurity 3
Pyrazinamide Impurity 3
CAS No.31722-48-2
Chemical FormulaC6H2N4
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 4 structure
4
吡嗪酰胺杂质4Pyrazinamide Impurity 4
Pyrazinamide Impurity 4
CAS No.98006-91-8
Chemical FormulaC6H5N3
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 5 structure
5
吡嗪酰胺杂质5Pyrazinamide Impurity 5
Pyrazinamide Impurity 5
CAS No.13924-96-4
Chemical FormulaC5H5N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 6 structure
6
吡嗪酰胺杂质6Pyrazinamide Impurity 6
Pyrazinamide Impurity 6
CAS No.133940-72-4
Chemical FormulaC6H4N6
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 7 structure
7
吡嗪酰胺杂质7Pyrazinamide Impurity 7
Pyrazinamide Impurity 7
CAS No.117856-61-8
Chemical FormulaC6H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 8 structure
8
吡嗪酰胺杂质8Pyrazinamide Impurity 8
Pyrazinamide Impurity 8
CAS No.122-05-4
Chemical FormulaC6H4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 10 structure
10
吡嗪酰胺杂质10Pyrazinamide Impurity 10
Pyrazinamide Impurity 10
CAS No.768-36-5
Chemical FormulaC5H5N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 12 structure
12
吡嗪酰胺杂质12Pyrazinamide Impurity 12
Pyrazinamide Impurity 12
CAS No.98135-38-7
Chemical FormulaC6H8N4O
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 13 structure
13
吡嗪酰胺杂质13Pyrazinamide Impurity 13
Pyrazinamide Impurity 13
CAS No.2844397-00-6
Chemical FormulaC5H5N5
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 16 structure
16
吡嗪酰胺杂质16Pyrazinamide Impurity 16
Pyrazinamide Impurity 16
CAS No.1391026-29-1
Chemical FormulaC6H3N5
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 21 structure
21
吡嗪酰胺杂质21Pyrazinamide Impurity 21
Pyrazinamide Impurity 21
CAS No.5181-05-5
Chemical FormulaC3H3N3
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 22 structure
22
吡嗪酰胺杂质22Pyrazinamide Impurity 22
Pyrazinamide Impurity 22
CAS No.28648-86-4
Chemical FormulaC5H5N3O
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 23 structure
23
吡嗪酰胺杂质23Pyrazinamide Impurity 23
Pyrazinamide Impurity 23
CAS No.1211528-24-3
Chemical FormulaC5H3FN2O2
Purity>95%询价On request
10mg25mg50mg100mg
Pyrazinamide Impurity 23 Lithium Salt structure
23
吡嗪酰胺杂质23 锂盐Pyrazinamide Impurity 23 Lithium Salt
Pyrazinamide Impurity 23 Lithium Salt
CAS No.2567495-97-8
Chemical FormulaC5H2FN2O2-·Li+
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

吡嗪酰胺 —— 研究文献与合成路线Pyrazinamide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 吡嗪酰胺 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Pyrazinamide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Pyrazinamide triggers degradation of its target aspartate decarboxylase
    Gopal P, Sarathy JP, Yee M, et al. · Nature communications · 2020 · 被引 104cited 104
  2. Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis
    Zhang S, Chen J, Shi W, et al. · Emerging microbes & infections · 2017 · 被引 40cited 40
  3. Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation
    Calleri E, De Lorenzi E, Furlanetto S, et al. · Journal of pharmaceutical and biomedical analysis · 2002 · 被引 34cited 34
  4. Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood
    Khuhawar MY, Rind FM · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2002 · 被引 43cited 43
  5. Simultaneous determination of rifampicin, isoniazid and pyrazinamide in tablet preparations by multivariate spectrophotometric calibration
    Goicoechea HC, Olivieri AC · Journal of pharmaceutical and biomedical analysis · 1999 · 被引 27cited 27
  6. Development and Validation of an HPLC Method for Simultaneous Determination of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride in Pharmaceutical Formulations
    Chellini PR, Lages EB, Franco PH, et al. · Journal of AOAC International · 2015 · 被引 14cited 14

合成与制备工艺专利Synthesis & process patents

  1. Preparation process of intermediate 2-cyanpyrazine of pyrazinamide drug
    LIN XUFENG XU · 公开号 CN1962647CN1962647 · 2007
  2. Pyrazinamide derivatives as well as preparation method and uses thereof
    XUEFANG SHI · 公开号 CN101182312CN101182312 · 2008
  3. Method for preparing isonicotinic acid and pyrazinamide by non-catalytic hydrolyzing isonicotinonitrile in near-critical water medium
    XIUYANG LU, HAOMING REN · 公开号 CN101475527CN101475527 · 2009
  4. Synthesis method of key intermediate 2-cyanpyrazine of tuberculosis drug pyrazinamide
    XU FANGXI LIN · 公开号 CN1962646CN1962646 · 2007
  5. Process for the preparation of pyrazinamide
    ZERGENYI JANOS DR, RAEZ BERNHARD, RAZ BERNHARD · 公开号 EP0122355EP0122355 · 1984

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

吡嗪酰胺 杂质谱研究要点Pyrazinamide — impurity profiling notes

下面这些是拿到 吡嗪酰胺 的 17 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 17 impurity entries for Pyrazinamide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances